Moleculin Biotech announced a 1-for-25 reverse stock split of its common stock.
The reverse stock split will take effect on December 1, 2025, on The Nasdaq Capital Market under the ticker symbol 'MBRX'.
The number of shares outstanding will decrease from approximately 51.7 million to 2.1 million shares.
Reverse Stock Split
1-for-25 reverse stock split will consolidate 25 shares into one issued share.
Stock Trading
Company's common stock to open for trading on December 1, 2025, with a new CUSIP number.
Share Reduction
Number of shares outstanding to be reduced to approximately 2.1 million shares.
- The reverse stock split aims to enhance the company's stock value and attract investors.
- Reducing the number of outstanding shares may signal confidence in the company's growth prospects.
Moleculin Biotech's decision for the reverse stock split reflects strategic restructuring to increase shareholder value and market appeal.